Table 3.

Predictors of new-onset AF for diabetic patients taking hypoglycemic agents after propensity score weighting

	Hazard ratio (95% CI); P value
	Univariate	Multivariate
DPP4i versus other hypoglycemic agents	0.65 (0.56–0.76); < 0.0001	0.69 (0.59–0.81); P < 0.0001
Age (years)
< 65	1.00 (reference)	1.00 (reference)
≥ 65	5.76 (4.97–6.68); < 0.0001	4.75 (4.07–5.55); P < 0.0001
Female gender	0.87 (0.75–1.01); 0.0714
Chronic lung disease	2.28 (1.46–3.56); 0.0003
Chronic kidney disease	1.74 (1.37–2.21); < 0.0001
Hypertension	2.64 (2.22–3.13); < 0.0001	1.74 (1.45–2.06); P < 0.0001
Ischemic heart disease	3.84 (2.88–5.13); < 0.0001	1.98 (1.48–2.66); P < 0.0001

ACEI angiotensin-converting-enzyme inhibitor, AF atrial fibrillation, ARB angiotensin II receptor antagonists, DM diabetes mellitus, DPP4i dipeptidyl peptidase-4 inhibitor, GLP-1 glucagon-like peptide-1, PAOD peripheral arterial obstructive disease, TZD thiazolidinedione